ReviewPharmacoEconomics2005
Economic implications of biological therapies for Crohn's disease: review of infliximab.
Review in PharmacoEconomics, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 28 citations in OpenAlex.
- Biologic agents for IBD: practical insights.Nature reviews. Gastroenterology & hepatology · 2015Review
- Economic implications of biological therapy for Crohn's disease.Przeglad gastroenterologiczny · 2015Review
- Current and future role of biomarkers in Crohn's disease risk assessment and treatment.Clinical and experimental gastroenterology · 2011Article
- The pharmacoeconomics of biologic therapy for IBD.Nature reviews. Gastroenterology & hepatology · 2010Review
- Capsule endoscopy in suspected small bowel Crohn's disease: economic impact of disease diagnosis and treatment.World journal of gastroenterology · 2009Article
- Emerging Issues in Gastroenterology and Hepatology.Gastroenterology & hepatology · 2009Review
- Demonstrating the value of biologics: a call to action.Biotechnology healthcare · 2007Article
- Treatment of Perianal Fistula and Abscess: Crohn's and Non-Crohn's.Current treatment options in gastroenterology · 2007Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crohn's disease is a chronic, relapsing inflammatory bowel disease that may require extensive medical and surgical interventions. Traditional therapies include 5-aminosalicylates, corticosteroids, immunosuppressants (e.g. azathioprine, mercaptopurine), defined formula diets, antibacterials and surgery. Infliximab is an anticytokine therapy for Crohn's disease that targets tumour necrosis factor-alpha. Infusions of infliximab have been shown to be superior to placebo in the induction and maintenance of remission in moderately severe and/or fistulising Crohn's disease. This review briefly summarises the data for clinical effectiveness of infliximab and then considers the economic implications of its use. Available economic modelling exercises suggest that infliximab has a relatively high incremental cost per QALY compared with standard care. However, there are limitations to these theoretical data and there has been no direct assessment of cost effectiveness within a controlled trial. Effective alternative treatment options for moderate-to-severe Crohn's disease are relatively lacking. More data are needed relating to the long-term safety of infliximab and the extent to which this new biological therapy produces lasting clinical benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.